Audit: QRS - Pycnogenol for Health & Longevity

Audit conducted on 10/08/2026 16:47 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	93
Passed	88
Failed	0
N/A	5
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS claims map to ER Conclusion, Protocol, Benefits, Risks, Interactions, Monitoring.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious framing preserved (very low certainty; speculative bleeding/glucose/BP; not proven lifespan therapy).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening of ER claims detected.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and interactions taken from Key Interactions & Contraindications; benefits/risks from their sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Pycnogenol brand and named drugs appear in the ER for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	No new expert or study attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Tone matches ER educational, non-prescriptive voice.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert, accessible, data-aware phrasing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Reads as evidence distillation, not a prescription.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No language implying medical advice beyond template footer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Presents information; no recommend/advise directives in variable content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No direct address of the reader in variable content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language in at-a-glance; technical terms in monitoring/interactions mirror ER.
2.8	Information is presented in a concise and very compact manner	🟢	Compact one-line tier lists and short protocol cells.
2.9	It DOES NOT address the reader directly	🟢	No second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framed for health/longevity-oriented adults.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes willingness to monitor markers and follow multi-week protocols.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not dumbed down for a non-optimizing general population.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Risk/benefit weighting matches ER longevity-optimization framing.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Uses longevity, not anti-aging.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical/scientific register for markers and interactions; no colloquial pill/shot language.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Fixed headings present: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, tier and table headers.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template data-qrs-var names present (actions, times, tiers, markers 1–6, qualitative 1–5, gates, at_a_glance, header fields).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website= spans and structural chrome left intact.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No fully empty ER section requiring empty-state phrasing; empty High tiers handled per 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Monitoring marker names and qualitative items follow ER wording; protocol short labels fit cell design.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker/qualitative labels not invented; match ER Monitoring content.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators in QRS content.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed into single-sheet structure without extra sections.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	YAML metadata HTML comment immediately after <!doctype html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening and closing — delimiters present.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Metadata only in HTML comment.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; duration quoted because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: pycnogenol_2026-0810-1543_Grok_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0810-1630
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Grok
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Nickname is single word Grok.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Grok 4
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Full name is nickname + version only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename matches document name.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Frontmatter values cleanly trimmed.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	page_title = “Pycnogenol for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	header_topic = “Pycnogenol for Health & Longevity”
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	header_subline_date 08/10/2026 from qrs_creation_date 2026-0810-1630
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model = Grok 4
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	No extra header badges or AKA lines.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	At-a-glance densifies ER Conclusion (uses, modest effects, very low certainty, low-risk add-on, not lifespan therapy).
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words (≤60).
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact supported in ER Conclusion / Benefits / Systematic Reviews framing.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses vessel lining, blood sugar, cholesterol markers; avoids specialist acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, RRs, or statistical results.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from ER Key Interactions & Contraindications avoid list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Five stop items match ER populations who should avoid.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is an <li>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing insufficient-data elaborations stripped; no dash-trailers.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	First-trimester and pre-/post-surgery qualifiers preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation to normalize.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section not empty; ER identifies avoid populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from ER Key Interactions & Contraindications.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven interaction bullets; none duplicated as contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is an <li>.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Caution/mechanism trailers after em-dashes stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug parentheticals preserved (warfarin, lisinopril, metformin, etc.).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation to normalize.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section not empty; ER lists interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Actions drawn from ER Therapeutic Protocol (dose, split dosing, multi-week evaluation).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Three actionable aspects: standard dose, split dosing, evaluation window.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct action sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All action_1–3 label/value/sub filled from Protocol.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Two time-to-effect aspects: endothelial/vascular (days–weeks) and venous & joint (2–12 weeks), matching MoA + Practical Considerations.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered by related medium-benefit magnitude (endothelial then venous/joint).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Third time set empty with parent pcell style=display:none.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Used time_1 and time_2 fully populated from ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information; section retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	From ER Expected Benefits.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	benefits_high hidden; medium/low/speculative populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Concise semicolon lists without effect sizes or study details.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Parentheticals stripped (e.g., erectile L-arginine note).
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high has style=”display:none”; no empty-state filler.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	From ER Potential Risks & Side Effects.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	risks_high hidden; medium/low/speculative populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Concise items without frequencies.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Parenthetical rash/mouth ulcers detail stripped from dermatologic item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high has style=”display:none”; no empty-state filler.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	From ER Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All six table biomarkers listed (BP, fasting glucose, HbA1c, LDL, hs-CRP, symptom score).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	monitoring_cadence matches ER ongoing monitoring paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	From ER Monitoring qualitative markers.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five qualitative markers listed.

Issues 10/08/2026 16:47

Pass rate 100.00%. No issues found.

Issues 10/08/2026 16:40

1. 1.4 — Discontinuation as TTE: time_3 places ER Discontinuation & Cycling reassessment language under Time to effect, relabeling a discontinuation fact into a time-to-effect slot.

2. 11.1 — Third TTE not from ER: time_3 (“Target-metric reassessment / 8–12 weeks”) is not among the ER’s stated time-to-effect aspects (vascular days-to-weeks; venous/joint 2–12 weeks).

3. 11.3 — Unused TTE slot filled: ER provides fewer than three distinct TTE aspects, but time_3 is populated rather than left empty and invisible.

4. 11.4 — time_3 not TTE content: time_3_label/value/sub use discontinuation reassessment wording, not ER-derived time-to-effect content.

Fixes 10/08/2026 16:41

1. 1.4 / 11.1 / 11.4 — Discontinuation TTE removed: Cleared time_3 label/value/sub that had used Discontinuation reassessment language under Time to effect.

2. 11.3 — Unused TTE slot hidden: Left time_3 empty and set the time_3 pcell to display:none, matching the two ER TTE aspects (vascular days-to-weeks; venous/joint 2–12 weeks).

Issues 10/08/2026 16:35

1. 1.1 — Unsupported cardiometabolic TTE: time_3 states cardiometabolic markers take “~3 months”; the ER uses ~3 months as monitoring recheck cadence, not as a stated time-to-effect for those markers. Children stop item also shortens beyond ER wording.

2. 1.3 — Children claim strengthened: stop_items “Children without specialist oversight” broadens the ER avoid-list item “Children under typical studied ages for a given indication without specialist oversight”.

3. 8.5 — Children age qualifier dropped: The ER qualifier “under typical studied ages for a given indication” is omitted from the children contraindication.

4. 11.1 — Third TTE not from ER: time_3 is not one of the ER’s stated time-to-effect aspects; ~3 months cardiometabolic onset is not supported as TTE.

5. 11.4 — time_3 monitoring as TTE: time_3_value/sub present monitoring language (“checked on multi-month horizon”) rather than ER-derived time-to-effect content.

Fixes 10/08/2026 16:36

1. 1.1 / 11.1 / 11.4 — Cardiometabolic TTE replaced: Changed time_3 from “Cardiometabolic markers / ~3 months / multi-month monitoring horizon” to “Target-metric reassessment / 8–12 weeks / no meaningful change at adequate dose limits justification,” matching the ER Discontinuation reassessment language.

2. 1.3 / 8.5 — Children qualifier restored: Replaced “Children without specialist oversight” with “Children under typical studied ages for a given indication without specialist oversight” from the ER avoid-list.